Extracellular Matrix News Volume 1.09 | Jun 24 2010

Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation
Studies of the human extracellular matrix produced under proprietary conditions of hypoxia and suspension have demonstrated its ability to diminish or eliminate tumor load in melanoma, breast cancer, colon cancer and glioma, both in vitro and in vivo. [Press release from Histogen, Inc. discussing research presented at the 8th Annual Meeting of the International Society for Stem Cell Research]

		Culture Human Mesenchymal Stem Cells in Serum-Free MesenCult®-XF by STEMCELL Technologies
		WATCH THE WEBINAR

First Working Replacement Lung Created in Lab
For the first time scientists have reconstructed working lungs in the lab and transplanted them into a living animal. [Press release from National Geographic discussing online prepublication in Science]

Researchers Create Self-Assembling Nanodevices That Move and Change Shape on Demand
By emulating nature’s design principles, researchers have created nanodevices made of DNA that self-assemble and can be programmed to move and change shape on demand. [Press release from the Wyss Institute for Biologically Inspired Engineering discussing online prepublication in Nature Nanotechnology]

Studying Cells in 3D Could Reveal New Cancer Targets
A new study indicates that viewing cell behavior in three dimensions could lead to important advances in cancer research. [Press release from Johns Hopkins University discussing online prepublication in Nature Cell Biology]

Scientists Successfully Engineer Heart Tissue
Scientists in China have successfully engineered myocardial tissue that is likely to share structural and functional similarities with natural myocardium. [Press release from the World Heart Federation discussing research presented at the World Congress of Cardiology 2010]

Tissue-Engineered Lungs for In Vivo Implantation
To explore whether lung tissue can be regenerated in vitro, researchers treated lungs from adult rats using a procedure that removes cellular components but leaves behind a scaffold of extracellular matrix that retains the hierarchical branching structures of airways and vasculature. [Science]

Self-Assembly of Three-Dimensional Prestressed Tensegrity Structures from DNA
Researchers report nanoscale, prestressed, three-dimensional tensegrity structures in which rigid bundles of DNA double helices resist compressive forces exerted by segments of single-stranded DNA that act as tension-bearing cables. [Nat Nanotechnol]

A Distinctive Role for Focal Adhesion Proteins in Three-Dimensional Cell Motility
Researchers show that membrane protrusions constitute a critical motility/matrix-traction module that drives cell motility in a 3D matrix. [Nat Cell Biol]

Regulation of Cell Motile Behavior by Crosstalk Between Cadherin- and Integrin-Mediated Adhesions
Results demonstrate that there is crosstalk between E-cadherin- and integrin-based adhesion complexes and that E-cadherin regulates lamellipodia activity and cell migration directionality, but not cell migration rate. [Proc Natl Acad Sci U S A]

Biochemical Characterization of the Cell-Biomaterial Interface by Quantitative Proteomics
Researchers revealed the enrichment of extracellular matrix proteins, membrane and stress fibers proteins at the adherence surface, while depleted those that belong to the cytoplasm, nucleus and lateral and apical membranes. [Mol Cell Proteomics]

Increased Expression of Alpha6 Integrin in Endothelial Cells Unveils a Proangiogenic Role for Basement Membrane
Researchers showed that the alpha6 integrin participated in vascular endothelial growth factor-A and fibroblast growth factor-2-driven angiogenesis in vitro and in vivo, suggesting that it might be an attractive target for therapeutic approaches in angiogenesis-dependent diseases such as tumor growth. [Cancer Res]

The Retention of Extracellular Matrix Proteins and Angiogenic and Mitogenic Cytokines in a Decellularized Porcine Dermis
A new decellularized porcine dermis material has been developed that retains many native extracellular matrix proteins and cytokines. [Biomaterials]

Hyaluronic Acid Hydrogels with Controlled Degradation Properties for Oriented Bone Regeneration
Hyaluronic acid hydrogel scaffold systems with tunable degradation properties were developed for the controlled delivery of osteoinductive and angiogenic growth factors, thus affecting the quantity and quality of regenerated tissue. [Biomaterials]

Effects of the Architecture of Tissue Engineering Scaffolds on Cell Seeding and Culturing
Researchers assessed the influence of scaffold pore architecture on immortalized mesenchymal stem cell seeding and static culturing, by comparing a computer-designed gyroid architecture fabricated by stereolithography to a random-pore architecture resulting from salt-leaching. [Acta Biomater]

SPARC/Osteonectin Functions to Maintain Homeostasis of the Collagenous Extracellular Matrix in the Periodontal Ligament
Results support the hypothesis that SPARC/osteonectin is critical in the control of tissue collagen content and indicate that SPARC/osteonectin is necessary for periodontal ligament homeostasis. [J Histochem Cytochem]

STEMCELL Technologies is Proud to Announce STEMcircles™, a Virus-Free Technology for Reprogramming Cells
STEMCELL Technologies, Inc. announced that they have signed a licensing agreement with Stanford University for a virus-free technique used for the generation of induced pluripotent stem cells. [STEMCELL Technologies, Inc. Press Release]

Kensey Nash Announces New Collagen Supply Agreement with St. Jude Medical
Kensey Nash Corporation announced that it entered into a new two-year Supply Agreement with St. Jude Medical, Inc. for the period from January 1, 2011 to December 31, 2012. [Kensey Nash Corporation Press Release]

Kensey Nash and Arthrex Announce Strategic Agreement for Extracellular Matrix Products
Kensey Nash Corporation and Arthrex, Inc. announced a strategic agreement regarding products developed from Kensey Nash’s unique extracellular matrix technology. [Kensey Nash Corporation Press Release]

Piramal Healthcare Limited to Acquire Assets of Biosyntech, a Biotechnology Company Developing Novel Products in Regenerative Medicine
Piramal Healthcare Limited announced signing of a definitive agreement to acquire BioSyntech’s assets for a consideration of CAD $3.9 million. [Piramal Healthcare Limited Press Release]

Valeant and Biovail Agree to Merge
Valeant and Biovail announced that both companies’ Boards of Directors have unanimously approved a definitive merger agreement under which the companies would combine to generate enhanced value for stockholders. The combined company will be called Valeant Pharmaceuticals International, Inc. [Biovail Corporation Press Release]

SEK 100 Million for Research into Regenerative Medicine
Karolinska Institutet has received a grant of SEK 100 million from the Knut and Alice Wallenberg Foundation for a regenerative medicine research centre — the Wallenberg Institute for Regenerative Medicine. [Karolinska Institutet Press Release]

Novus Scientific Announces the Sales Launch for TIGR™ Matrix Surgical Mesh — World’s First Long-Term Resorbable Synthetic Mesh
Novus Scientific, Inc. announced the U.S. sales launch of TIGR™ Matrix Surgical Mesh. [Novus Scientific, Inc. Press Release]

FDA Told to Step Up Oversight of Offshore Clinical Trials
The Food and Drug Administration (FDA) hasn’t done enough to monitor clinical trial data coming from overseas sites and patients, which increasingly dominate the studies used to support U.S. drug applications, according to a report from the Department of Health and Human Services’ inspector general. [Department of Health and Human Services, United States]

New Videos Reveal How NIH Identifies the Most Promising Research Applications
The National Institutes of Health’s (NIH) Center for Scientific Review released a new video to show new applicants and others how NIH assesses over 80,000 grant applications each year to help find those with the most merit. [National Institutes of Health, United States]

FDA Pushes Orphan Drug Research
The Food and Drug Administration (FDA) published a list of 235 treatments that may have benefit in rare disorders and already have marketing clearance for other uses. [Food and Drug Administration, United States]

President of EFPIA Calls for a ‘New Dialogue’ on Medicines
Andrew Witty, CEO of GlaxoSmithKline and President of European Federation of Pharmaceutical Industries and Associations (EFPIA), the body representing the research-based pharmaceutical industry in Europe, called for ‘a new dialogue’ between governments and the pharmaceutical industry in order to deliver patient access to better medicines and enhance Europe’s competitiveness as a base for R&D investment. [European Federation of Pharmaceutical Industries and Associations, European Union]

Publication of New Enforcement Strategy
A new enforcement strategy has been published by the Inspection, Enforcement and Standards Division. [Medicines and Healthcare Products Regulatory Agency, United Kingdom]

Proposal Review Panel for Materials Research; Notice of Meeting [National Science Foundation, United States]

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting [National Institutes of Health, United States]

Risk Evaluation and Mitigation Strategy Public Meeting [Center for Biologics Evaluation and Research, United States]

Presentations About the Regulation of Blood and Tissues  [Therapeutic Goods Administration, Australia]

EVENTS

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

UK Society for Biomaterials Annual Conference
July 1-2, 2010
Glasgow, Scotland

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

Regenerative Medicine Iasi (ReMedIs) 2010
July 15-18, 2010
Iasi, Romania

The Tissue & Cell Engineering Society 2010 Meeting
July 28-30, 2010
Manchester, United Kingdom

2nd International Conference on Cellular and Molecular Bioengineering (ICCMB2)
August 2-4, 2010
Singapore

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

The European Molecular Biology Organization (EMBO) Meeting – Advancing the Life Sciences
September 4-7, 2010
Barcelona, Spain

23rd European Conference on Biomaterials
September 11-15, 2010
Tampere, Finland

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States 

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

15th Congress of the European Society of Surgical Oncology (ESSO)
September 15-17, 2010
Bordeaux, France

9th Annual Human Proteome Organization (HUPO) World Congress
September 19-23, 2010
Sydney, Australia

Symposium on Advanced Wound Care
September 23-25, 2010
Anaheim, United States

4th International Conference on Biofabrication
October 4-6, 2010
Philadelphia, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

BioStar 2010 – 4th Congress on Regenerative Biology and Medicine
October 13-15, 2010
Stuttgart, Germany

American Society for Matrix Biology (ASMB) 2010 Biennial Meeting
October 24-27, 2010
Charleston, United States

Select Biosciences 2nd Annual Lab-on-a-Chip World Congress
October 28-29, 2010
San Diego, United States

Fraunhofer Life Science Symposium 2010
October 29-30, 2010
Leipzig, Germany

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC)
November 12-13, 2010
Tianjin, China

Medica 2010
November 17-20, 2010
Dusseldorf, Germany

Translational Excellence in Regenerative Medicine – Biophysical Stimuli and Mass Transport for Tissue Development
November 18-19, 2010
Lattrop, The Netherlands

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – North America 2010 Annual Conference
December 5-8, 2010
Orlando, United States

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Senior Scientist – Magnetic Cell Separation (STEMCELL Technologies)

Business Development Manager Europe – Cell Therapy Products (Pall Corporation)

Manager/Sr. Manager, Therapeutic Cell Solutions, Process Development (Lonza)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here  to post your career opportunities.

Have we missed an important article or publication in Extracellular Matrix News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com  with your feedback.